|
Gender
differences in symptoms and care delivery for chronic obstructive pulmonary disease
CH Martinez, S Raparla, CA Plauschinat, ND Giardino, B Rogers,
...
Journal of women's health 21 (12), 1267-1274
|
112 |
2012 |
|
Clinical and
economic outcomes among patients with diabetes mellitus initiating insulin glargine pen
versus vial
M Grabner, J Chu, S Raparla, R Quimbo, S Zhou, J Conoshenti
Postgraduate medicine 125 (3), 204-213
|
46 |
2013 |
|
Cost-sharing and
initiation of disease-modifying therapy for multiple sclerosis.
J Romley, D Goldman, M Eber, H Dastani, E Kim, S Raparla
The American journal of managed care 18 (8),
460-464
|
43 |
2012 |
|
The INITIATOR
study: pilot data on real-world clinical and economic outcomes in US patients with type
2 diabetes initiating injectable therapy
S Thayer, W Wei, E Buysman, L Brekke, W Crown, M Grabner, S
Raparla, ...
Advances in therapy 30 (12), 1128-1140
|
29 |
2013 |
|
Evaluation of
cardiovascular risk factors, events, and costs across four BMI categories
DI Brixner, M Bron, BK Bellows, X Ye, J Yu, S Raparla, GM
Oderda
Obesity 21 (6), 1284-1292
|
17 |
2013 |
|
Synthesis of
zidovudine derivatives with anti-HIV-1 and antibacterial activities
P Senthilkumar, J Long, R Swetha, V Shruthi, RR Wang, S
Preethi, ...
Nucleosides, Nucleotides and Nucleic Acids 28 (2),
89-102
|
12 |
2009 |
|
Systematic
Literature Review of Real-World Effectiveness Results Data for First-Line Ibrutinib in
Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: P. Lee et al.
P Lee, KD Kistler, L Douyon, R Volodarsky, A Young, S Karve,
...
Drugs-Real World Outcomes 10 (1), 11-22
|
11 |
2023 |
|
Gender
differences in the COPD resource network needs assessment survey 2007
CH Martinez, S Raparla, CA Plaushinat, EL Stanley, B Rogers, J
Bersford, ...
American Thoracic Society International Conference
Meetings Abstracts 183 …
|
6 |
2011 |
|
Similar efficacy
of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic
lymphocytic leukemia: a matching-adjusted indirect comparison
M Shadman, A Tedeschi, L Mohseninejad, K Yang, N Lamanna, S
Xu, ...
Blood Cancer Journal 14 (1), 77
|
5 |
2024 |
|
Prospective
patient preference study for Bruton tyrosine kinase inhibitor (BTKi) treatment
attributes and factors affecting patient shared decision-making in chronic …
S Ailawadhi, S Challagulla, TI Totev, D Pilon, Y Meng, M Xue,
Z Chen, ...
Expert Review of Hematology 19 (3), 321-331
|
3 |
2026 |
|
Patient
medication preferences in follicular lymphoma in the United States: a discrete choice
experiment
S Gaballa, M Xue, TI Totev, D Pilon, Y Meng, S Challagulla, Z
Chen, ...
Postgraduate Medicine 138 (2), 214-223
|
3 |
2026 |
|
Real-world
treatment utilization patterns, discontinuation, and healthcare resource utilization of
first-line bruton tyrosine kinase inhibitor therapy in chronic lymphocytic …
K Yang, S Challagulla, PY Chuang, W Furnback, S Ailawadhi
Clin Lymphoma Myeloma Leuk 25, S537-S538
|
3 |
2025 |
|
Real-world
treatment switching and sequencing to next line of therapy of zanubrutinib,
acalabrutinib, and ibrutinib in CLL/SLL
J Pinilla-Ibarz, M Xue, E Wu, K Esselman, W Furnback, S
Challagulla, ...
J Clin Oncol 42 (16_suppl), e19022
|
3 |
2024 |
|
Real-world
evaluation of treatment discontinuation and healthcare resource utilization in patients
with chronic lymphocytic leukemia or small lymphocytic lymphoma
AA Chanan-Khan, S Challagulla, E Donckels, PY Chuang, K Yang
Blood 142, 5144
|
3 |
2023 |
|
Impact of
Real-World Treatment Sequencing Patterns on Time to Next Treatment among Patients with
Chronic Lymphocytic Leukemia in the United States
AA Chanan-Khan, S Challagulla, A Kaushiva, V Miller, Y Wang, H
Smith, ...
Blood 142, 5143
|
3 |
2023 |
|
Real-world
treatment utilization patterns, discontinuation and healthcare resource utilization of
first-line Bruton tyrosine kinase inhibitors among elderly patients≥ 65 years …
S Ailawadhi, S Challagulla, PY Chuang, W Furnback, K Yang
Expert Review of Hematology 19 (5), 539-546
|
2 |
2026 |
|
Patient
medication preferences in follicular lymphoma (FL) in the United States (USA): a
discrete-choice experiment (DCE)
S Gaballa, M Xue, TI Totev, Y Meng, S Challagulla, Z Chen, K
Yang
Blood 144, 3655
|
2 |
2024 |
|
Similar efficacy
of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic
lymphocytic leukemia: a matching-adjusted indirect comparison
M Shadman, A Tedeschi, L Mohseninejad, K Yang, N Lamanna, S
Xu, ...
Blood 142, 4655
|
2 |
2023 |
|
Zanubrutinib
versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell
lymphoma
B Shah, S Challagulla, S Xu, R Williams, S Ren, T Srivastava,
R Gautam, ...
Leukemia & Lymphoma 66 (12), 2238-2248
|
1 |
2025 |
|
Prospective
Patient Preference Study for Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment
Attributes and Factors Affecting Patient Shared Decision-Making in Chronic …
S Ailawadhi, S Challagulla, D Pilon, Y Meng, M Xue, Y Wang, K
Yang
Blood 144, 2265
|
1 |
2024 |
|
MCL-509 Indirect
Comparison of Efficacy of Zanubrutinib Versus Acalabrutinib in the Treatment of
Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)
B Shah, S Challagulla, S Xu, R Williams, S Ren, T Srivastava,
R Gautam, et al.
Clinical Lymphoma Myeloma and Leukemia 24,
S516-S517
|
1 |
2024 |
|
Comparison of
zanubrutinib (zanu) and acalabrutinib (acala) in B-cell malignancies: An adverse event
(AE)-based analysis
T Munir, Y Wang, L Mohseninejad, T Srivastava, A Gupta, R
Gautam, et al.
Journal of Clinical Oncology 42 (16_suppl),
e19049-e19049
|
1 |
2024 |
|
Impact of dosing
frequency of oral oncolytics on refill adherence among patients with hematological
malignancies
S Challagulla, N Kebede, S Rege, RR Volodarsky, K Osei-Bonsu,
S Karve
Blood 138, 1964
|
1 |
2021 |
|
Initiation of
new injectable treatment introduced after anti-diabetic therapy with oral-only regimens
(INITIATOR) study: an interim analysis
J Chu, W Wei, E Buysman, S Thayer, L Brekke, WH Crown, M
Grabner, et al.
Diabetologia 56, S107-S107
|
1 |
2013 |
|
PDB6 Real-World
Comparative Effectiveness Analysis of Patients Initiating Injectable Treatments for Type
2 Diabetes Mellitus (T2DM): Pilot Data From the Initiator Study
M Grabner, W Wei, S Raparla, RA Quimbo, MJ Cziraky, SW Thayer,
et al.
Value in Health 15 (7), A494
|
1 |
2012 |
|
Real-world
practice patterns, clinical and economic outcomes among US patients with type 2 diabetes
initiating once-daily injectable pen therapy with insulin glargine
S Raparla, W Wei, M Grabner, RM Cuddihy, W Hu, R Quimbo
Journal of General Internal Medicine 27, S293-S293
|
1 |
2012 |
|
Prospective
patient preference study for chronic lymphocytic leukemia (CLL) treatment attributes
impacting patient shared decision-making
S Ailawadhi, S Challagulla, Y Meng, TI Totev, D Pilon, L Diaz,
Z Chen, et al.
Expert Review of Anticancer Therapy
|
– |
2026 |
|
Estimated
cardiac deaths associated with treating chronic lymphocytic leukemia with ibrutinib
versus zanubrutinib in the United States
JR Brown, T Munir, AH Lipsky, S Challagulla, D Campbell, K
Yang, Q Fu, et al.
Future Oncology 22 (19), 2271-2278
|
– |
2026 |
|
Navigating the
post–covalent bruton tyrosine kinase inhibitor (cBTKi) landscape in mantle cell lymphoma
(MCL): Real-world insights on treatment patterns, discontinuation, and healthcare
resource utilization
AJ Alencar, S Challagulla, D Yuan, Q Fu, K Yang, TA Eyre
Journal of Clinical Oncology 44 (16_suppl),
7058-7058
|
– |
2026 |
|
RWD14 A
comprehensive global systematic literature review of real-world evidence of
relapsed/refractory and post-Bruton tyrosine kinase inhibitor mantle cell lymphoma
A Alencar, S Challagulla, C Abreu, J Kim, M Dec, W Furnback, K
Yang
Value in Health 29 (6), S405
|
– |
2026 |
|
Efficacy of
sonrotoclax vs pirtobrutinib in post–Bruton tyrosine kinase inhibitor (BTKi)
relapsed/refractory (R/R) mantle cell lymphoma (MCL): An indirect comparison
AJ Alencar, S Challagulla, K Wang, L Mohseninejad, P
Wojciechowski, et al.
Journal of Clinical Oncology 44 (16_suppl),
e19050-e19050
|
– |
2026 |
|
Real-world
treatment switching and sequencing to next line of therapy of zanubrutinib,
acalabrutinib, and ibrutinib in chronic lymphocytic leukemia or small lymphocytic
lymphoma
J Pinilla-Ibarz, M Xue, E Wu, K Esselman, W Furnback, S
Challagulla, et al.
Expert Review of Hematology 19 (4), 457-464
|
– |
2026 |
|
Patients with
high-risk features in Mantle Cell Lymphoma: A systematic literature review of clinical
trials and real-world studies
C Ryan, S Challagulla, W Furnback, M Xue, K Yang, A Alencar
Blood 146, 8103
|
– |
2025 |
|
Estimated
cardiac deaths associated with treating chronic lymphocytic leukemia with ibrutinib
versus zanubrutinib in the United States
J Brown, S Challagulla, D Campbell, Q Fu, W Aldairy, K Yang, R
Williams, et al.
Blood 146, 7443
|
– |
2025 |
|
Chemo±immunotherapy remains utilized for
chronic lymphocytic lymphoma in the real-world practice: Unmet needs, treatment
patterns, and age disparities in the United States
J Pinilla-Ibarz, S Challagulla, Q Fu, P Cheng, M Xue, K Yang
Blood 146, 2762
|
– |
2025 |
|
Real-world
treatment utilization, sequencing, and outcomes in Mantle Cell Lymphoma: Emerging
treatment patterns in the United States
A Alencar, M Xue, Q Fu, D Yuan, S Challagulla, K Yang
Blood 146, 8020
|
– |
2025 |
|
POSTER: CLL-1077
Prospective Patient Preference Study for Chronic Lymphocytic Leukemia (CLL) Treatment
Attributes Impacting Patient Shared Decision-Making
S Ailawadhi, S Challagulla, D Pilon, TI Totev, Y Meng, L Diaz,
Z Chen, et al.
Clinical Lymphoma Myeloma and Leukemia 25, S212
|
– |
2025 |
|
POSTER: CLL-1065
Real-World Treatment Utilization Patterns, Discontinuation, and Healthcare Resource
Utilization of First-Line Bruton Tyrosine Kinase Inhibitor Therapy in Chronic
Lymphocytic Leukemia
K Yang, S Challagulla, PY Chuang, W Furnback, S Ailawadhi
Clinical Lymphoma Myeloma and Leukemia 25, S212
|
– |
2025 |
|
CLL-1065:
Real-World Treatment Utilization Patterns, Discontinuation, and Healthcare Resource
Utilization of First-Line Bruton Tyrosine Kinase Inhibitor Therapy in Chronic
Lymphocytic Leukemia
K Yang, S Challagulla, PY Chuang, W Furnback, S Ailawadhi
Clinical Lymphoma Myeloma and Leukemia 25,
S537-S538
|
– |
2025 |
|
549| Prospective
Patient Preference Study for Chronic Lymphocytic Leukemia Treatment Attributes Impacting
Patient Shared-Decision Making
S Ailawadhi, S Challagulla, D Pilon, TI Totev, Y Meng, L Diaz,
Z Chen, et al.
Hematological Oncology 43, 1
|
– |
2025 |
|
Real-world
outcomes of patients receiving oral specialty therapy for the treatment of chronic
lymphocytic leukemia/small lymphocytic leukemia at an integrated health system
C Renfro, H Wyatt, S White, A Zuckerman, H Holloway, J
DeClercq, et al.
Current Medical Research and Opinion 40, S13-S13
|
– |
2024 |
|
Real-World
Treatment Switching and Sequencing to Next Line of Therapy of Zanubrutinib,
Acalabrutinib, and Ibrutinib in Chronic/Small Lymphocytic Leukemia (CLL/SLL)
J Pinilla-Ibarz, M Xue, E Wu, K Esselman, W Furnback, S
Challagulla, et al.
Clinical Lymphoma, Myeloma and Leukemia 24, S184
|
– |
2024 |
|
CLL-534
Real-World Treatment Switching and Sequencing to Next Line of Therapy of Zanubrutinib,
Acalabrutinib, and Ibrutinib in Chronic/Small Lymphocytic Leukemia (CLL/SLL)
J Pinilla-Ibarz, M Xue, E Wu, K Esselman, W Furnback, S
Challagulla, et al.
Clinical Lymphoma Myeloma and Leukemia 24,
S358-S359
|
– |
2024 |
|
Indirect
comparison of efficacy of zanubrutinib versus acalabrutinib in the treatment of
relapsed/refractory mantle cell lymphoma
BD Shah, S Challagulla, S Xu, R Williams, S Ren, T Srivastava,
R Gautam, et al.
|
– |
2024 |
|
Time to Next
Treatment, Healthcare Resource Utilization, and Healthcare Costs Among Patients with
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following First-Line Therapy
S Challagulla, B Emond, RR Volodarsky, A Young, A Manceur, S
Karve
Blood 138, 4016
|
– |
2021 |
|
PCN95 Effect of
Earlier Use of Ibrutinib on Healthcare Resource Utilization (HRU) and Costs Among
Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma
S Challagulla, P Lee, N Giafis, AM Manceur, I Fakih, B Emond,
R Iyengar
Value in Health 24, S37
|
– |
2021 |
|
PCN101
Real-World Economic Outcomes of First-Line (1L) Ibrutinib Treatment in Patients With
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
S Challagulla, P Lee, K Kistler, L Douyon, D Lai, R Iyengar
Value in Health 24, S38
|
– |
2021 |
|
PCN300
Systematic Literature Review of Patient-Reported Outcome Measures Used in Mantle Cell
Lymphoma
K Miu, S Challagulla, D Arthur, JK Neuenburg, R Iyengar
Value in Health 23, S76
|
– |
2020 |
|
PDB3 How
Different Were They? A Treatment Pattern Analysis of United States Patients With Type 2
Diabetes Mellitus (T2DM) Initiating Injectable Therapy
V Walker, W Wei, S Thayer, L Brekke, W Crown, M Grabner, S
Raparla, et al.
Value in Health 15 (7), A493
|
– |
2012 |
|
Prevalence and
Cost of Cardiovascular Events Predicted By Body Mass Index Risk Factors: A Decision Tree
Analysis
DI Brixner, M Bron, BK Bellows, X Ye, J Yu, S Raparla, G
Oderda
Obesity 19, S228-S228
|
– |
2011 |
|
Comparative
Efficacy of Once-Daily Indacaterol 75 µg in COPD in Terms of Forced Expiratory Volume: A
Patient Level Network Meta-analysis
S Cope, J Zhang, S Raparla, J Williams, J Jansen
Chest 140 (4), 556A
|
– |
2011 |